Sotrovimab
Monoclonal antibody / From Wikipedia, the free encyclopedia
Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2.[10][11][12] It was developed by GlaxoSmithKline and Vir Biotechnology, Inc.[11][13] Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.[11][12][14]
Quick Facts Monoclonal antibody, Type ...
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Spike protein of SARS-CoV-2 |
Clinical data | |
Trade names | Xevudy |
Other names | VIR-7831, GSK4182136 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a621037 |
License data |
|
Pregnancy category | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
DrugBank | |
UNII | |
KEGG |
Close
The most common side effects include hypersensitivity (allergic) reactions and infusion-related reactions.[10]
Although Sotrovimab was used world-wide against SARS-CoV-2, including in the United States under an FDA emergency use authorization (EUA), the FDA canceled the EUA in April 2022 due to lack of efficacy against the Omicron variant. [15]